- Extra on BMRN’s Q3 Earnings
- Voxzogo — A Key Driver of BioMarin’s Prime Line
- Gross sales Efficiency of BMRN’s Enzyme Therapies
- Different Revenues
- BMRN’s 2025 Outlook
- BMRN to Divest Roctavian
- BMRN’s Current Pipeline Updates
- BMRN’s Zacks Rank
- BioMarin Pharmaceutical Inc. Worth
- Our Key Picks Amongst Biotech Shares
- Quantum Computing Shares Set To Soar
BioMarin Pharmaceutical BMRN reported third-quarter 2025 adjusted earnings per share (EPS) of 12 cents towards the Zacks Consensus Estimate of a lack of 15 cents. Quarterly earnings plummeted practically 87% yr over yr, primarily because of IPR&D fees of $221 million recorded by the firm in reference to the not too long ago accomplished acquisition of Inozyme Pharma.
Complete revenues have been $776 million, up 4% yr over yr. Nevertheless, the determine missed the Zacks Consensus Estimate of $784 million.
Yr up to now, shares of BioMarin have misplaced 20% towards the business’s 10% development.
Picture Supply: Zacks Funding Analysis
Extra on BMRN’s Q3 Earnings
Product revenues totaled practically $761 million, up 4% yr over yr on greater revenues from Voxzogo and Palynziq. This was partially offset by decrease gross sales of Aldurazyme and Kuvan.
Royalty and different revenues totaled over $15 million, up 29% yr over yr.
Voxzogo — A Key Driver of BioMarin’s Prime Line
Voxzogo, accepted for achondroplasia, generated gross sales of $218 million, up 15% yr over yr, pushed by new sufferers initiating the remedy throughout ex-U.S. territories. This development was partially offset by unfavorable order timing fluctuations throughout the quarter.
In the USA, uptake was stronger amongst youngsters beneath two years of age, whereas adoption amongst older youngsters remained slower. The corporate is implementing initiatives to increase therapy on this section, which it expects will take time to point out outcomes.
Owing to those components, Voxzogo gross sales missed each the Zacks Consensus Estimate of $234 million and our mannequin estimates of $231 million.
Gross sales Efficiency of BMRN’s Enzyme Therapies
Final yr, the corporate up to date its organizational construction and determined to consolidate revenues from its 5 merchandise — Aldurazyme, Brineura, Naglazyme, Palynziq and Vimizim — beneath a single head, ‘Enzyme Therapies.’ Gross sales of this franchise rose 1% yr over yr to $516 million.
Palynziq injection gross sales totaled $109 million within the quarter, up 20% yr over yr, pushed by higher numbers of sufferers titrating to the daily-maintenance dose and robust adherence. The drug’s gross sales beat each the Zacks Consensus Estimate and our mannequin estimates of $103 million and $107 million, respectively.
Vimizim gross sales rose 3% yr over yr to $183 million, which missed each the Zacks Consensus Estimate of $192 million and our mannequin estimate of $188 million.
Naglazyme gross sales declined 8% yr over yr to $122 million, because of unfavorable timing of huge authorities orders in Latin America. Brineura added gross sales of $48 million, up 30%.
Product revenues from Aldurazyme totaled $54 million, down 24% yr over yr, as a result of unfavorable timing of order achievement to Sanofi SNY.
BioMarin signed a collaboration settlement with Sanofi’s subsidiary, Genzyme, for Aldurazyme. SNY, by Genzyme, is BMRN’s sole buyer for Aldurazyme. The Sanofi subsidiary is accountable for advertising and marketing and promoting Aldurazyme to 3rd events.
Different Revenues
New gene remedy, Roctavian, generated $3 million in gross sales in contrast with $7 million within the year-ago interval.
Within the phenylketonuria (PKU) franchise, Kuvan revenues declined 14% to $24 million because of generic competitors. The drug misplaced U.S. market exclusivity in late 2020.
BMRN’s 2025 Outlook
BioMarin revised its monetary steerage for the complete yr. It now expects whole revenues within the vary of $3.15-$3.20 billion, which displays a $25 million improve from the decrease finish of the earlier steerage of $3.13-$3.20 billion. The improve in steerage implies a rise of greater than 11% yr over yr on the midpoint.
The corporate expects Voxzogo to be a major contributor to the highest line, forecasting gross sales within the $900-$935 million band (unchanged). The drug’s revenues are anticipated to achieve their highest degree in 2025 throughout This autumn.
Adjusted working margin is now anticipated to be between 26% and 27%, in contrast with the prior expectations of 33-34%. This downward revision primarily displays bills incurred throughout the third quarter to shut the Inozyme acquisition.
Because of the Inozyme acquisition, BioMarin additionally lowered its adjusted EPS steerage, which is now anticipated to be within the vary of $3.50-$3.60, down from the prior forecast of $4.40-$4.55. This revised steerage implies 1% development over final yr’s degree on the midpoint.
Throughout theearnings name BioMarin introduced that it’s rescinding its beforehand issued monetary steerage for 2027, primarily because of aggressive issues round Voxzogo and the choice to divest Roctavian. The corporate additionally famous that enterprise growth stays a high strategic precedence. CEO Alexander Hardy highlighted that BioMarin is actively pursuing a number of partnership and acquisition alternatives, together with late-stage and industrial property. It cited an estimated $4-$5 billion in whole “firepower” obtainable for future development initiatives, supporting its disciplined capital allocation and enterprise growth technique.
BMRN to Divest Roctavian
Alongside the earnings outcomes, BioMarin introduced plans to divest Roctavian and take away it from its portfolio of marketed merchandise. This resolution is a part of the corporate’s technique to concentrate on areas that align with its strategic priorities.
Within the meantime, BioMarin will proceed to market the gene remedy throughout the USA, Italy and Germany, till a remaining resolution is made.
BMRN’s Current Pipeline Updates
In April, BioMarin reported optimistic outcomes from the late-stage PEGASUS examine, which confirmed that adolescents with PKU handled with Palynziq achieved a statistically vital reducing in blood Phe ranges. Primarily based on this knowledge, the corporate will goal regulatory filings for expanded use of the medicine in adolescents in the USA and Europe later this yr.
BioMarin continues to advance its CANOPY scientific program, which evaluates Voxzogo for a possible second indication — hypochondroplasia, a situation characterised by impaired bone development. Information from this examine is predicted within the first half of 2026. As a part of this program, BMRN can also be evaluating the drug for 4 different short-stature pathway situations — idiopathic brief stature, Noonan Syndrome, Turner Syndrome and SHOX deficiency.
Primarily based on the success seen with Voxzogo as a C-type natriuretic peptide (CNP) analog, BioMarin determined to advance BMN 333 — a long-acting formulation of CNP — as a possible therapy for a number of growth-related situations, providing the choice for much less frequent dosing. The corporate plans to start out a registration-enabling part II/III examine within the first half of 2026, aiming for a possible 2030 launch.
The Inozyme acquisition added an investigational late-stage enzyme alternative remedy referred to as BMN 401 (previously INZ-701), which is being developed in a late-stage examine to deal with a uncommon dysfunction referred to as ENPP1 deficiency in youngsters aged 1-12. Preliminary outcomes from this examine are anticipated within the first half of 2026.
BioMarin expects to report preliminary proof-of-concept knowledge from an early-stage examine on BMN 351, an oral therapeutic for liver illness related to alpha-1 antitrypsin deficiency, earlier than this yr’s finish.
BMRN’s Zacks Rank
BioMarin at present has a Zacks Rank #4 (Promote).
BioMarin Pharmaceutical Inc. Worth
BioMarin Pharmaceutical Inc. value | BioMarin Pharmaceutical Inc. Quote
Our Key Picks Amongst Biotech Shares
Some better-ranked shares from the sector are Alkermes ALKS and Werewolf Therapeutics HOWL. Whereas ALKS sports activities a Zacks Rank #1 (Robust Purchase) at current, HOWL carries a Zacks Rank #2 (Purchase). You’ll be able to see the whole listing of immediately’s Zacks #1 Rank shares right here.
EPS estimates for Alkermes’ 2025 have elevated from $1.81 to $1.85, whereas these for 2026 have risen from $1.68 to $1.70 previously 60 days. ALKS inventory has gained practically 4% yr up to now.
Alkermes’ earnings beat estimates in two of the trailing 4 quarters and missed the mark on the opposite two events, delivering a median unfavorable shock of 1.19%.
Prior to now 60 days, loss per share estimates for Werewolf Therapeutics’ 2025 have improved from $1.88 to $1.61. Loss per share estimates for 2026 have narrowed from $1.61 to $1.36 throughout the identical interval. HOWL inventory has gained over 12% yr up to now.
Werewolf’s earnings beat estimates in three of the trailing 4 quarters however missed the mark as soon as, delivering a median shock of seven.36%.
Quantum Computing Shares Set To Soar
Synthetic intelligence has already reshaped the funding panorama, and its convergence with quantum computing may result in essentially the most vital wealth-building alternatives of our time.
Right now, you’ve got an opportunity to place your portfolio on the forefront of this technological revolution. In our pressing particular report, Past AI: The Quantum Leap in Computing Energy, you may uncover the little-known shares we consider will win the quantum computing race and ship large positive aspects to early traders.
Sanofi (SNY) : Free Inventory Evaluation Report
BioMarin Pharmaceutical Inc. (BMRN) : Free Inventory Evaluation Report
Alkermes plc (ALKS) : Free Inventory Evaluation Report
Werewolf Therapeutics, Inc. (HOWL) : Free Inventory Evaluation Report
This text initially revealed on Zacks Funding Analysis (zacks.com).
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially replicate these of Nasdaq, Inc.
